Intel stock spikes after report of possible US government stake
In a recent transaction, Lilly Endowment Inc, a significant shareholder of Eli Lilly & Co (NYSE:LLY), sold a substantial portion of its holdings. According to a Form 4 filing with the Securities and Exchange Commission, the endowment disposed of shares amounting to a total value of approximately $203 million.
The sales occurred on February 25, 2025, comprising several transactions at prices ranging from $900.501 to $911.549 per share. Following these transactions, Lilly Endowment Inc now holds 96,236,978 shares of Eli Lilly. The company maintains strong fundamentals with an "GOOD" Financial Health score from InvestingPro, which highlights 18 additional key insights available to subscribers.
These transactions highlight the ongoing financial activities of major stakeholders in Eli Lilly, a leading pharmaceutical company headquartered in Indianapolis. The sales were executed under the direct ownership of Lilly Endowment Inc, as indicated in the filing. Notable is the company’s impressive 55-year track record of maintaining dividend payments, demonstrating long-term financial stability.
In other recent news, Eli Lilly has announced plans to invest over $50 billion in U.S. manufacturing, marking a significant expansion with the construction of four new pharmaceutical sites. This investment, the largest in the history of U.S. pharmaceutical manufacturing, aims to bolster production capabilities across various therapeutic areas, including active pharmaceutical ingredients and injectable therapies. Additionally, Eli Lilly is expanding its self-pay program by introducing new dosage options and reducing prices for existing vials, a move aimed at increasing accessibility for patients without substantial insurance coverage. Analyst firms like Deutsche Bank (ETR:DBKGn), JPMorgan, and BMO Capital Markets have maintained positive ratings on Eli Lilly, with price targets ranging from $1,010 to $1,100, reflecting confidence in the company’s strategic initiatives. The upcoming Phase 3 trial results for Eli Lilly’s drug candidate orforglipron, developed for Type 2 Diabetes and obesity, are anticipated to be pivotal for the company’s trajectory. The trials are expected to show results by 2025, with analysts predicting competitive efficacy but slightly lower tolerability compared to current treatments. Eli Lilly’s CEO has emphasized the expansion’s potential benefits for American families and the prospect of increasing exports of U.S.-made medicines. The company’s strategic moves, including the direct-to-consumer channel LillyDirect, are seen as efforts to enhance patient access and strengthen market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.